Prednisolone

Evidence Level: L2

Predicted Indications: 9

Prednisolone

Pharmacist Assessment Report

Prednisolone: From Autoimmune and Inflammatory Diseases to Alopecia Areata

One-Sentence Summary

Prednisolone is a systemic glucocorticoid originally used for autoimmune and inflammatory conditions (such as Crohn disease, inflammatory bowel disease and adrenocortical insufficiency), as well as for certain leukaemias. The TxGNN model predicts it may be effective for alopecia areata, with no registered clinical trials but 20 publications (including a network meta-analysis, systematic reviews and a placebo-controlled trial of oral pulse prednisolone) supporting this direction.

Quick Overview

Item	Content
Original Indication	Autoimmune disease, Crohn disease and inflammatory bowel disease, adrenocortical insufficiency, acute lymphoblastic leukaemia (the Canadian licence record contains no indication text)
Predicted New Indication	Alopecia areata
TxGNN Prediction Score	0.9999
Evidence Level	L2
Canada Market Status	Marketed (marketed DINs: 1 of 1)
Number of DINs	1 (marketed: 1)
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Detailed mechanism of action data is not currently available. Based on known information, prednisolone is a glucocorticoid whose efficacy in autoimmune and inflammatory disease is well established, and mechanistically it may be applicable to alopecia areata.

Alopecia areata is a T-cell-mediated autoimmune attack on hair follicles, with a collapse of the follicle’s immune privilege. Glucocorticoids suppress T-cell activation and pro-inflammatory cytokines, which directly addresses this pathology. One included study also reports changes in serum and tissue TNF-α levels as a possible mechanism of oral pulse steroids in this disease.

The original indications already include several autoimmune and inflammatory diseases, so extending to another autoimmune condition is a natural step. The main limitations are relapse after treatment is withdrawn and the toxicity of long-term systemic steroids, which is why pulse regimens are the focus of the literature.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
37870096	2023	Network meta-analysis	Cochrane Database Syst Rev	Compares treatments for alopecia areata, including immunosuppressants, hair growth stimulants and contact immunotherapy
30191561	2019	Systematic review	Australas J Dermatol	Evaluates the evidence for systemic treatments in alopecia areata, totalis and universalis; efficacy evidence is variable
15692475	2005	Placebo-controlled trial	J Am Acad Dermatol	Oral pulse prednisolone in alopecia areata; earlier studies had not been randomised or placebo-controlled
37992355	2023	Review	Dermatol Pract Concept	Reviews efficacy, relapse rates, side effects and prognostic factors of pulse corticosteroids
36461625	2023	Review	Pediatr Dermatol	Pulse corticosteroid dosing in children with alopecia areata; regimens are not well established
28140540	2017	Clinical study	J Dtsch Dermatol Ges	Sequential high- then low-dose systemic steroids in severe childhood alopecia areata; high doses give the best and fastest response, but relapse follows discontinuation
21572877	2009	Clinical study	Dermatoendocrinol	Medium-dose prednisolone pulse therapy; effective in early stages, but significant side effects may lead to discontinuation
12051021	2002	Clinical study	J Formos Med Assoc	High-dose steroid pulse therapy in 17 Taiwanese patients with severe alopecia areata
9720702	1998	Clinical study	Pediatr Dermatol	Monthly oral prednisolone pulse in 16 young patients with widespread alopecia areata
26179196	2015	Long-term follow-up	Dermatol Ther	Combined oral pulse and topical corticosteroids in 65 children with severe alopecia areata, median follow-up 96 months

Canada Market Information

DIN	Product Name	Dosage Form	Approved Indication
02245532	PMS-PREDNISOLONE	Not stated	Not stated

Safety Considerations

Disease associations flagged in the knowledge graph (not label text): the knowledge graph links prednisolone with contraindications including hypertension, congestive heart failure, hyperglycaemia, epilepsy, herpes simplex keratitis, measles, porphyria, and several urea cycle and pituitary-related disorders. These should be checked against the product label.
Drug Interactions: 100 interactions were identified in total. Among those reviewed, the one rated Major is adalimumab. Moderate interactions include ibuprofen, ketorolac, nifedipine, ethinylestradiol, isotretinoin, acarbose, acetazolamide, aldesleukin, alemtuzumab and aliskiren. Minor interactions include formoterol and salbutamol.
Treatment-related risks noted in the literature: relapse after withdrawal and systemic steroid toxicity limit long-term use.

Please refer to the package insert for full warnings and contraindications.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Evidence for alopecia areata includes a network meta-analysis, systematic reviews and a placebo-controlled oral pulse prednisolone trial, and the mechanism fits a T-cell-mediated autoimmune disease. However, no registered trials are available, relapse after withdrawal is common, and long-term systemic steroid toxicity limits use.

To proceed, the following is needed:

Health Canada package insert warnings and contraindications, which are currently missing
Mechanism of action data
Registered or new controlled trials with defined pulse dosing regimens, especially in children
A relapse-management and steroid-toxicity monitoring plan (growth, bone, infection and metabolic effects)
A review of interactions, particularly with adalimumab

Other Predicted Indications (Brief)

Predicted Indication	Evidence Level	Decision	Note
Idiopathic steroid-sensitive nephrotic syndrome	L1	Proceed with Guardrails	Already standard first-line therapy, so better viewed as an existing use than true repurposing. Retrieved literature largely concerns steroid-resistant disease, a different population
Alopecia mucinosa	L5	Hold	Only a cyclosporine case report; no prednisolone data
Folliculitis decalvans	L4	Hold	Only a triple-therapy case report
Telogen effluvium, hereditary hypotrichosis with recurrent skin vesicles, alopecia antibody deficiency, alopecia-intellectual disability-hypergonadotropic hypogonadism syndrome, atrichia with papular lesions, prolapse of lacrimal gland	L5	Hold	Computational prediction only, with no plausible mechanistic link

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.